Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster

Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster

Submitted by admin on July 8, 2024 - 11:54am
Source: 
Fierce Biotech
News Tags: 
Eli Lilly
Morphic
M&A
Takeda
Entyvio
IBD
Headline: 
Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster
snippet: 

Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio.

Do Not Allow Advertisers to Use My Personal information